Compare AbbVie Inc (ABBV) vs Stanley Black & Decker, Inc. (SWK) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Stanley Black & Decker, Inc. — how do they compare? AbbVie Inc trades at $254 (market cap $449.91B), while Stanley Black & Decker, Inc. trades at $86.16 (market cap $13.89B). The key difference: AbbVie Inc is far larger — about 32.4× Stanley Black & Decker, Inc.'s market cap, and Stanley Black & Decker, Inc. pays the higher dividend (3.71%). Which is the better fit depends on your goals.
| ABBV | SWK | |
|---|---|---|
Market Cap | $449.91B | $13.89B |
Sector | Health | — |
52-Week High | $261.07 | $94.12 |
52-Week Low | $184.85 | $62.12 |
Enterprise Value | $513.38B | $20.06B |
Dividend Yield | 2.72% | 3.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $252.92, down 0.72% on the day, with strong technical support at $251 and resistance at $258. The stock shows bullish momentum with recent earnings beats and a consensus analyst price target of $266.33. Revenue grew to $61.16B in 2025, though net margins compressed to 5.79%. Key growth drivers include Skyrizi and Rinvoq offsetting Humira declines, supported by positive Phase 2 data for ELAHERE in ovarian cancer (PRNewsWire, 2026-04-12).
Outlook remains positive with immunology portfolio strength and dividend growth, but risks include patent cliffs in the 2030s and high debt levels. Institutional buying and 68% analyst buy ratings suggest confidence, though valuation multiples like P/E of 124.83 warrant caution. Near-term catalysts include Q2 2026 earnings expected at $3.79 EPS.
Stanley Black & Decker (SWK) trades at $89.37, down 2.75% today, with a bullish technical signal from moving averages but neutral oscillators. The company has beaten earnings estimates for three consecutive quarters, with Q2 2026 results pending. Revenue trends show stabilization around $15B annually, while net income improved to $401.9M in 2025. Debt reduction remains a priority, supported by positive operating cash flow of $971.2M.
SWK offers a turnaround story with improving profitability and shareholder returns via dividends, but faces headwinds from weak Tools & Outdoor demand and high debt levels. Analyst consensus is mixed with a $82.75 price target below current levels, suggesting cautious optimism amid execution risks and macroeconomic pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Stanley Black & Decker, Inc.
Stanley Black & Decker Inc is a manufacturer of hand and power tools. The company operates three business segments: tools and storage, security, and industrial. Tools and storage, the largest segment by revenue, sells hand tools and power tools to professional end-users, distributors, retail consumers, and industrial customers. Security installs electronic security systems and provides electronic security services including alarm monitoring and video surveillance. Industrial sells engineered fastening products such as stud-welding systems, blind inserts and tools, and engineered plastic and mechanical fasteners. The largest end market is the United States of America.
Read more on SWK →
